Literature DB >> 7605316

Analgesia and sedation in interventional radiological procedures.

C Y Hiew1, G K Hart, K R Thomson, O F Hennessy.   

Abstract

The use of intravenous analgesia and anxiolytics in interventional radiology improves the patient's tolerance of potentially painful and prolonged procedures and allows the radiologist better control of the course of the procedure being undertaken. Monitoring of the patient's oxygen saturation, pulse rate, respiration, blood pressure and cardiac rhythm during a procedure is essential. Fentanyl and midazolam is a combination that is effective and convenient to use because both agents are relatively short acting, have little cardiovascular depression and are easily reversible (with naloxone and flumazenil). They are a better alternative to pethidine and diazepam because they can be more tightly titrated and controlled and are safer and more suitable for use in outpatients. Monitoring for respiratory depression is important and special care must be taken in the elderly and patients with hepatic, renal or chronic airways disease. General anaesthesia may be unavoidable in patients who are unstable, unco-operative or who have raised intracranial pressure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605316     DOI: 10.1111/j.1440-1673.1995.tb00256.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  2 in total

1.  Effect of an oral anxiolytic medication and heart rate variability on image quality of 64-slice MDCT coronary angiography.

Authors:  R Cubuk; N Tasali; S Yilmazer; P Gokalp; L Celik; B Dagdeviren; S Guney
Journal:  Radiol Med       Date:  2010-09-17       Impact factor: 3.469

2.  A prospective randomized controlled trial assessing the effect of music on patients' anxiety in venous catheter placement procedures.

Authors:  Florian Nima Fleckenstein; Agnes Klara Böhm; Federico Collettini; Anne Frisch; Willie Magnus Lüdemann; Elif Can; Bernhard Gebauer; Martin Jonczyk
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.